CoChat
Sign Up
Cited by 96Breast Cancer Treatment StudiesGrowth Hormone and Insulin-like Growth FactorsCancer Risks and Factors

Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer

Mulligan, Anna Marie, O’Malley, Frances P., Ennis, Marguerite, Fantus, I. George, Goodwin, Pamela J.·2007·Breast Cancer Research and Treatment
DOI 10.1007/s10549-006-9471-x
Open this paper in CoChat — free account

Abstract

Fasting insulin is related to outcome in early breast cancer. We evaluated the expression of insulin receptor (IR) and its prognostic significance in patients with early stage breast cancer. Tumors from 191 patients with T1-3, N0-1, M0 breast cancer who were enrolled at a single center of a multicenter cohort study were used to construct microarrays with subsequent immunohistochemical evaluation of IR, IGF-IR, ER, PgR and HER2/neu. Correlation of biomarker expression with traditional prognostic factors, serum biochemistry (notably insulin) and clinical outcome was assessed. IR was strongly positive (Allred score = 8) in 54% of tumors. High IR expression significantly correlated with favorable prognostic markers (low tumor grade, lymph node negativity and progesterone receptor positivity) but not with fasting levels of circulating insulin. At a median follow-up of 9.1 years, high vs. low IR expression (an Allred score of 8 vs. 0-7) was associated with statistically significant improved distant disease-free survival (multivariate hazard ratio (HR) = 0.4; P = 0.027) and overall survival (multivariate HR = 0.26; P = 0.005). IR is highly expressed in the majority of early stage breast cancers but this expression is not clearly down-regulated in the presence of high insulin levels. Furthermore, high expression of IR is independently and significantly associated with more favorable clinical outcomes. Follow-up intervention research is recommended.

Integrity signals

Registry

Crossref · 10.1007/s10549-006-9471-x

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Higher levels of insulin receptor compared with ligand have been associated with favorable breast cancer prognosis in some studies.

    “Compared with the ligand (i.e., insulin), higher levels of insulin receptor have been associated with favorable breast cancer prognosis in some studies (60,61).”

    From Diabetes and Cancer (2010) · cites this paper as [60]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Mulligan, A. M., O’Malley, F. P., Ennis, M., Fantus, I. G., & Goodwin, P. J.
Affiliations
Mount Sinai Hospital (CA)
Corresponding author
Goodwin, Pamela J.
ORCID
Venue
Breast Cancer Research and Treatment
Publisher
Springer Science and Business Media LLC
Published
2007-01-13
Volume
106
Issue
1
Pages
39-47
ISSN
  • 0167-6806 (ISSN-L)
  • 1573-7217
DOI
10.1007/s10549-006-9471-x
OpenAlex
W1980674859
Cited by
96
References
41
Citations by year
2026: 1 · 2025: 2 · 2024: 1 · 2023: 2 · 2022: 3 · 2021: 4 · 2020: 6 · 2019: 5 · 2018: 3 · 2017: 5 · 2016: 3 · 2015: 7 · 2014: 5 · 2013: 8 · 2012: 8
FWCI
2.58
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Breast Cancer Research and Treatment (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
  • Health Sciences › Medicine › Oncology › Cancer Risks and Factors
Keywords
insulin receptor, early breast cancer, prognostic factors, insulin, IGF-1 receptor, Allred score, distant disease-free survival, overall survival, progesterone receptor, estrogen receptor, HER2/neu, tumor grade, lymph node status
MeSH terms
Adult, Aged, Breast Neoplasms, Female, Follow-Up Studies, Humans, Immunohistochemistry, Insulin, Middle Aged, Neoplasm Staging, Ontario, Receptors, Estrogen, Receptor, Insulin, Receptors, Progesterone, Time Factors, Biomarkers, Tumor, Odds Ratio, Treatment Outcome, Receptor, IGF Type 1, Risk Assessment, Disease-Free Survival, Erb-b2 Receptor Tyrosine Kinases, Tissue Array Analysis, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review